The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Glasdegib given positive opinion by the EMA CHMP for use in patients with newly diagnosed AML
On April 30, 2020, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion recommending approval of glasdegib, in combination with low-dose cytarabine (LDAC), for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in patients ineligible for standard chemotherapy.
Glasdegib is an oral smoothened inhibitor decreasing glioma-associated oncogene transcription factor activity. It is already approved by the United States Food and Drug Administration (FDA), in combination with LDAC, for the treatment of patients with newly diagnosed AML ineligible for chemotherapy.
Glasdegib is well tolerated, with the most frequent severe adverse event being fatigue, and improves overall survival when used in combination with LDAC. In the ‘How I treat’ series in Blood, which covers the use of new drugs in different case studies, Courtney DiNardo and Andrew Wei reported that, even though the overall response rate for glasdegib plus LDAC was modest, the combination had better survival compared with LDAC alone in a randomized trial (read more here).
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?